Syndesmophyte Growth in Ankylosing Spondylitis: from Laboratory to Bedside.

IF 5.7 2区医学 Q1 RHEUMATOLOGY Current Rheumatology Reports Pub Date : 2023-07-01 DOI:10.1007/s11926-023-01104-x

Michael M Ward, Sovira Tan

{"title":"Syndesmophyte Growth in Ankylosing Spondylitis: from Laboratory to Bedside.","authors":"Michael M Ward, Sovira Tan","doi":"10.1007/s11926-023-01104-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: This study aims to review recent studies on risk factors for syndesmophyte growth in ankylosing spondylitis (AS) and on treatment effects.Recent findings: New genetic studies, including a genome-wide association study, provided only limited evidence of specific genetic associations with radiographic severity. Measures of inflammation, including vertebral osteitis and C-reactive protein level, were strongly associated with radiographic progression, while studies of adipokines had mixed results. Mesenchymal stem cells from HLA-B27 positive AS patients were found to promote vertebral ossification via a pathway of B27 misfolding, retinoic acid receptor-β activation, and increased bone alkaline phosphatase. Low vertebral trabecular bone density is associated with syndesmophyte growth, with reciprocal effects when bridged. Several observational studies suggested radiographic severity was reduced by treatment with tumor necrosis factor inhibitors, particularly when longer than 2 years. Syndesmophyte development in AS is the result of a complex, incompletely understood, interplay of inflammatory and mechanical factors.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"25 7","pages":"119-127"},"PeriodicalIF":5.7000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-023-01104-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This study aims to review recent studies on risk factors for syndesmophyte growth in ankylosing spondylitis (AS) and on treatment effects.

Recent findings: New genetic studies, including a genome-wide association study, provided only limited evidence of specific genetic associations with radiographic severity. Measures of inflammation, including vertebral osteitis and C-reactive protein level, were strongly associated with radiographic progression, while studies of adipokines had mixed results. Mesenchymal stem cells from HLA-B27 positive AS patients were found to promote vertebral ossification via a pathway of B27 misfolding, retinoic acid receptor-β activation, and increased bone alkaline phosphatase. Low vertebral trabecular bone density is associated with syndesmophyte growth, with reciprocal effects when bridged. Several observational studies suggested radiographic severity was reduced by treatment with tumor necrosis factor inhibitors, particularly when longer than 2 years. Syndesmophyte development in AS is the result of a complex, incompletely understood, interplay of inflammatory and mechanical factors.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

强直性脊柱炎伴生菌生长:从实验室到床边。

综述目的:本研究旨在综述强直性脊柱炎(AS)伴发真菌生长的危险因素及治疗效果的最新研究。最新发现:新的遗传学研究，包括一项全基因组关联研究，仅提供了有限的证据，证明特定的遗传与放射学严重程度有关。炎症的测量，包括椎体骨炎和c反应蛋白水平，与放射学进展密切相关，而脂肪因子的研究结果则好坏参半。来自HLA-B27阳性AS患者的间充质干细胞通过B27错误折叠、视黄酸受体-β激活和骨碱性磷酸酶增加的途径促进椎体骨化。低椎骨小梁骨密度与副骨生长有关，桥接时相互作用。几项观察性研究表明，使用肿瘤坏死因子抑制剂治疗可降低放射学的严重程度，特别是治疗时间超过2年。AS伴生菌的发育是炎症和机械因素复杂而不完全了解的相互作用的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.